Bergen Open Research Archive >
Faculty of Medicine >
Institute of Medicine >
Section for Haematology >
Denne identifikatoren kan du bruke til å sitere eller lenke til denne innførselen:
http://hdl.handle.net/1956/2453
|
| Tittel: | Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway |
| Forfattere: | Wergeland, Line |
| Dato: | 6-Sep-2007 |
| Forlag: | The University of Bergen |
| Sammendrag: | Acute myeloid leukemia (AML) is an aggressive disease with a poor overall
survival rate. The most frequent mutations associated with AML are internal tandem
duplications (ITD) in the juxtamembrane region of the receptor tyrosine kinase Flt3.
These mutations render the receptor constitutively active and alter signaling trough
FLT3-ITD compared to wild type receptor. Non-mutated TP53 and elevated
expression of its regulator Hdm2 is another interesting feature of AML. Studies have
shown that the p53 pathway can be linked to Flt3 signaling as a subset of FLT3-ITD
patients expresses increased levels of the anti-apoptotic protein Bcl-2 and hyperphosphorylated
p53 protein. This thesis investigates the properties of FLT3-ITD and
the interconnection of the Flt3 signaling pathway with the p53/Hdm2/Bcl-2 pathway
in an attempt to elucidate novel therapeutic targets in AML.
The experiments demonstrate a reciprocal regulation of Flt3 and Hdm2 in AML
cells with Flt3-wt while FLT3-ITD cells suspend the Hdm2 modulation. FLT3-ITD
patient cells have a higher level of Flt3 protein and the ITD results in dysregulated
receptor turnover and attenuated Hdm2 down-regulation. Thus targeting of FLT3-ITD
may result in elevated Hdm2 and increased tolerance for p53. The involvement of
Bcl-2 family of proteins is also seen in this setting; a persistent attenuation of Mcl-1
is required for the cells to undergo apoptosis, however this is only seen in Flt3-wt
cells. Hdm2 is in addition shown to be important as a regulator of Bcl-2. The
blockage of Hdm2 E3 ligase activity results in increased Bcl2 and Hdm2 is required
for Bcl-2 protection from p53-induced cell death.
To conclude, wild type and mutated Flt3 is interconnected with the important
p53/Hdm2/Bcl-2 pathway at several levels. Therapeutic targeting of Flt3 should
therefore be evaluated in co-operation with the p53/Hdm2/Bcl-2 pathway. Combined
targeting of FLT3-ITD, Hdm2 and Bcl-2 may therefore be interesting when
approaching the development of novel AML therapy. |
| URI: | http://hdl.handle.net/1956/2453 |
| ISBN: | 978-82-308-0417-9 (print version) |
| Vises i samlingene: | Section for Haematology
|
Alle innførsler i BORA er beskyttet av opphavsrett
